Liposomal Composition for Ambient Weak-Acid Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering weak acid drugs, such as prostaglandins, face challenges including poor encapsulation efficiency, instability at ambient temperatures, and the need for high-frequency dosing due to short half-life and side effects from overdosing, particularly in conventional liposomal formulations.
Innovation Solution
A liposomal composition is developed using a lipid mixture with a hydrophilic polymer conjugated lipid at less than 3% molar percentage, allowing encapsulation of a weak acid salt at ambient temperature, and incorporating a polyprotic acid to enhance retention and stability, enabling sustained release and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If heating step is used to increase permeability of prostaglandins into liposomes, then encapsulation efficiency is improved, but drug degradation accelerates and stability deteriorates
Solution Approach 1:
The patent changes the temperature parameter from elevated (>60°C) to ambient temperature (25°C) for the loading process. This parameter change allows encapsulation to proceed without thermal degradation of the prostaglandin drug, resolving the contradiction between achieving sufficient encapsulation efficiency and maintaining drug stability.
Solution Approach 2:
The patent introduces an intermediary mechanism using a pH gradient (proton shuttle) across the liposome membrane instead of thermal energy. The pH difference between inner and outer aqueous phases creates a driving force for drug accumulation without requiring heating, thus maintaining drug stability while achieving encapsulation.
2Reliability
If conventional liposomal formulation is used, then drug delivery is achieved, but encapsulation efficiency is poor leading to overdose problems
Solution Approach 1:
The patent modifies the pH parameters by creating a pH gradient across the liposome membrane through proton shuttle mechanism. This parameter change enables high encapsulation efficiency (>85%) which prevents free drug circulation and overdose problems, while maintaining reliable drug delivery to target sites.
3Duration of action of moving object
If weak acid drug is administered frequently to overcome short half-life, then therapeutic effect is maintained, but side effects from overdosing increase
Solution Approach 1:
The patent utilizes the phase transition of the drug between ionized and non-ionized forms based on pH differences. The drug accumulates in the liposome interior where pH differs from external environment, creating a reservoir that releases drug gradually. This extends therapeutic duration while preventing overdose side effects through controlled release rather than frequent dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high encapsulation efficiency (>85%) and stability for at least one year, allowing for extended dosing intervals and reduced side effects, making it suitable for clinical use.
Implementation Method 1
the interior space is separated from the aqueous medium by a membrane comprised of a lipid mixture
Implementation Method 2
the lipid mixture contains one or more lipids and a hydrophilic polymer conjugated lipid at a molar percentage of less than 3% based on the total amount of the lipid mixture
Data Source
AI summary
Provided is a method for preparing a liposomal composition. The method comprises the step of contacting a liposome solution with a mild acidic agent for a limited time. The liposome solution comprises a weak acid salt encapsulated within an aqueous interior space separated from the aqueous medium by a membrane comprised of a lipid mixture containing one or more lipids and a hydrophilic polymer conjugated lipid at a molar percentage of less than 3% based on the total amount of the lipid mixture. The time for encapsulating the agent to a desired amount at a predetermined ratio to lipids is dramatically reduced even under a condition without elevating the temperature to above ambient environment.